Lyophilized GM-CSF Neutralizing Formulation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current protein pharmaceutical formulations, particularly those containing Granulocyte-macrophage colony stimulating factor (GM-CSF), face challenges in stability and aggregation, leading to reduced bioactivity and increased immunogenicity, especially at high concentrations, which complicates subcutaneous administration and storage.
Innovation Solution
A stable lyophilized formulation comprising an antibody binding to GM-CSF, optimized with histidine, sucrose, and polysorbate 80, which minimizes aggregation and maintains stability at high concentrations, allowing for effective subcutaneous administration and long-term storage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If protein pharmaceuticals are stored in liquid formulation, then ease of manufacture and convenience for end user are improved, but protein stability deteriorates over extended storage periods
Solution Approach 1:
The patent applies parameter changes by transitioning the formulation from liquid to lyophilized (freeze-dried) state, which fundamentally alters the physical and chemical parameters of the protein pharmaceutical. This phase change from liquid to solid amorphous or crystalline state reduces molecular mobility, suppresses degradation reactions, and enhances long-term stability while maintaining reconstitutable functionality for end-user convenience.
Solution Approach 2:
The patent utilizes phase transitions through the lyophilization process, which involves freezing the liquid formulation and then sublimating the ice under vacuum. This phase transition from liquid → solid (ice) → solid (lyophilized cake) creates a stable dry state that preserves protein integrity during storage, while the reverse transition upon reconstitution restores functionality for administration.
2Stability of the object's composition
If protein pharmaceuticals are lyophilized, then protein stability and ease of shipping/storage are improved, but convenience for end user deteriorates
Solution Approach 1:
The patent applies preliminary action by performing lyophilization in advance during manufacturing, creating a stable dry powder formulation that can be stored and shipped without degradation. The end user only needs to perform the simple reconstitution step by adding solvent, which restores the liquid formulation for administration. This shifts the complex stabilization process to the manufacturing stage while keeping the user stage simple.
3Ease of manufacture
If polypeptides are stored in solution, then ease of manufacture is improved, but aggregation and degradation occur during long-term storage
Solution Approach 1:
The patent utilizes phase transitions through lyophilization to convert the liquid pharmaceutical formulation into a solid dry state. This phase change removes the aqueous environment that facilitates aggregation and degradation reactions, while the frozen-dried matrix preserves molecular integrity. The process maintains ease of manufacture by using standard biopharmaceutical processing steps.
4Quantity of substance
If high concentration of GM-CSF neutralizing compound is used, then therapeutic efficacy is improved, but aggregation and immunogenicity increase
Solution Approach 1:
The patent applies parameter changes by optimizing the formulation composition including pH, ionic strength, and excipient concentrations to enable high stability at high protein concentrations (up to 100 mg/mL). The lyophilized state further allows dense packing of molecules in a stable amorphous or crystalline matrix, achieving high drug load while minimizing aggregation through controlled freeze-drying parameters.
Solution Approach 2:
The patent uses composite materials by combining the GM-CSF neutralizing compound with stabilizing excipients such as sugars (sucrose, trehalose), amino acids (histidine), and surfactants (polysorbate 80). This composite formulation creates a protective matrix that maintains high protein concentration while preventing aggregation and reducing immunogenicity through molecular spacing and surface passivation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves significant stability and bioactivity retention, reducing aggregation and immunogenicity, enabling effective subcutaneous administration and prolonged shelf life without significant viscosity increase, thus addressing the challenges of protein stability and bioactivity in GM-CSF formulations.
Implementation Method 1
stable lyophilized formulations comprising a compound neutralizing Granulocyte-macrophage colony stimulating factor (GM-CSF)
Implementation Method 2
The ingredients of the formulations preferably provide stability over lyophilization, storage and reconstruction
Implementation Method 3
A stable lyophilized formulation comprising an antibody binding to GM-CSF, optimized with histidine, sucrose, and polysorbate 80
Implementation Method 4
A stable lyophilized formulation comprising an antibody binding to GM-CSF, optimized with histidine, sucrose, and polysorbate 80
Data Source
AI summary
The present invention relates to aqueous formulations comprising at least 20 mg/ml of a compound neutralizing GM-CSF, a lyoprotectant and an amino acid and/or a buffer. The ingredients of the formulation preferably provide stability to the compound neutralizing GM- CSF in view of lyophilisation, storage and reconstruction. In a preferred aspect, the formulation, e.g. after reconstruction,is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders. Furthermore, a kit comprising the formulation of the invention is provided.